![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
AAO 2024: Epimacular membranes and metamorphopsia
2024年10月20日 · At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.
Clinical trials: Companies tackle AMD in early 2024 - Modern Retina
2024年4月2日 · Age-related macular degeneration continues to be a key development area for many pharmaceutical companies as the work to develop new treatment options and present data in the first few months of the year.
Ocugen will continue second phase of OCU410 ArMaDa clinical trial
2025年1月3日 · The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 (AAV5-hRORA), is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Peter Chang, MD, FACS, Co-President and ...
AAO 2024: An update from Neurotech on its MacTel treatment …
2024年10月18日 · Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well as their upcoming presentations at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois.
Curcuma-based nutritional supplements and reduced risk of AMD
2024年10月25日 · The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration (AMD) or progression to the later disease stages, 1 according to the first author Amer F. Alsoudi, MD, from the Department of Ophthalmology, Baylor College of Medicine, Houston. He was joined in ...
US FDA issues Complete Response Letter for avacincaptad pegol ...
2024年11月19日 · Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for avacincaptad pegol intravitreal solution (IZERVAY). In the November 15 CRL, the FDA stated it cannot approve a supplemental New Drug Application in its present form. IZERVAY had an expected Prescription Drug User Fee Act (PDUFA) date of November 19. In a press ...
Light therapy: Potential treatment for dry AMD - modernretina.com
The results of a new study has shown that photobiomodulation, a non-invasive treatment, may be another method for treating dry age-related macular degeneration (AMD). David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, reported that this therapy can reduce the risk of visual loss and show disease progression. Boyer reported the results at the 2024 American Academy ...
Exegenesis Bio provides an update on EXG102 and EXG202 for wet …
2024年12月11日 · Exegenesis Bio provided an update on the company’s treatment candidates for wet age-related macular degeneration (wet AMD). EXG102 is an investigational gene therapy for wet AMD that is administered by subretinal injection. EXG202, a next generation version, incorporates the same genetic cargo as EXG102, but is delivered to deep retinal cells by a highly-specific ocular capsid that enables ...
Distinction between lamellar holes and macular pseudoholes
2018年3月12日 · By Vanessa Caceres; Reviewed by John T. Thompson, MD. Continuity of the external limiting membrane (ELM)/ellipsoid layers can help to identify eyes with lamellar macular holes that are likely to benefit from surgery, according to John T. Thompson, MD. Dr. Thompson of Retina Specialists, Baltimore, MD, addressed two types of partial thickness macular holes-lamellar macular holes and ...
Eyecare wrapped: Top stories from Modern Retina in 2024
2024年12月26日 · Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.